Bionano Genomics, Inc. (BNGO) Stock

Healthcare · Medical Instruments & Supplies · Member of Other US Stocks

Bionano Genomics, Inc. (BNGO) closed at USD 1.37 on 2026-10-14, a change of -26.7 % over the past year, with a market capitalization of USD 16.13M.

Bionano Genomics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Bionano Genomics, Inc. key figures

Previous close

USD 1.37 (2026-10-14)

1-year change

-26.7 %

Market cap

USD 16.13M

Enterprise value

USD 12.92M

P/E ratio (trailing)

-0.45

P/E ratio (forward)

-1.41

EPS (trailing)

-3.02

EPS (forward)

-0.97

PEG ratio

n/a

Price to book

0.51

Revenue growth

21.4 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.85

Employees

95

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Bionano Genomics, Inc.

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Bionano Genomics, Inc. and compare it with other stocks.